Vor Biopharma Inc has a consensus price target of $13.75 based on the ratings of 10 analysts. The high is $22 issued by Baird on March 24, 2023. The low is $4 issued by Goldman Sachs on May 24, 2022. The 3 most-recent analyst ratings were released by JMP Securities, Oppenheimer, and Wedbush on May 13, 2024, May 13, 2024, and May 10, 2024, respectively. With an average price target of $11 between JMP Securities, Oppenheimer, and Wedbush, there's an implied 1108.53% upside for Vor Biopharma Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/13/2024 | Buy Now | 1218.39% | JMP Securities | Silvan Tuerkcan | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
05/13/2024 | Buy Now | 998.66% | Oppenheimer | Matthew Biegler | $15 → $10 | Reiterates | Outperform → Outperform | Get Alert |
05/10/2024 | Buy Now | 1108.53% | Wedbush | David Nierengarten | → $11 | Reiterates | Outperform → Outperform | Get Alert |
04/23/2024 | Buy Now | 1108.53% | Wedbush | David Nierengarten | → $11 | Reiterates | Outperform → Outperform | Get Alert |
03/22/2024 | Buy Now | 1218.39% | JMP Securities | Silvan Tuerkcan | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
03/21/2024 | Buy Now | 1822.65% | HC Wainwright & Co. | Swayampakula Ramakanth | → $17.5 | Reiterates | Buy → Buy | Get Alert |
03/21/2024 | Buy Now | 1108.53% | Wedbush | David Nierengarten | — | Reiterates | Outperform → Outperform | Get Alert |
03/21/2024 | Buy Now | 1218.39% | Stifel | Stephen Willey | $15 → $12 | Maintains | Buy | Get Alert |
03/21/2024 | Buy Now | 1547.99% | Oppenheimer | Matthew Biegler | $17 → $15 | Reiterates | Outperform → Outperform | Get Alert |
01/18/2024 | Buy Now | 1108.53% | Wedbush | David Nierengarten | → $11 | Reiterates | Outperform → Outperform | Get Alert |
08/14/2023 | Buy Now | 1218.39% | JMP Securities | Silvan Tuerkcan | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
08/11/2023 | Buy Now | 1108.53% | Wedbush | David Nierengarten | $18 → $11 | Maintains | Outperform | Get Alert |
08/11/2023 | Buy Now | 1822.65% | HC Wainwright & Co. | Swayampakula Ramakanth | → $17.5 | Reiterates | Buy → Buy | Get Alert |
06/12/2023 | Buy Now | 1822.65% | HC Wainwright & Co. | Swayampakula Ramakanth | → $17.5 | Reiterates | Buy → Buy | Get Alert |
05/16/2023 | Buy Now | 1822.65% | HC Wainwright & Co. | Swayampakula Ramakanth | → $17.5 | Reiterates | Buy → Buy | Get Alert |
05/16/2023 | Buy Now | 1877.59% | JonesTrading | Justin Walsh | → $18 | Initiates | → Buy | Get Alert |
05/15/2023 | Buy Now | 1877.59% | Oppenheimer | Matthew Biegler | → $18 | Reiterates | Outperform → Outperform | Get Alert |
05/12/2023 | Buy Now | 1877.59% | Wedbush | David Nierengarten | → $18 | Reiterates | Outperform → Outperform | Get Alert |
03/24/2023 | Buy Now | 1657.86% | Truist Securities | Stephen Willey | $17 → $16 | Maintains | Buy | Get Alert |
03/24/2023 | Buy Now | 1657.86% | Stifel | Stephen Willey | $17 → $16 | Maintains | Buy | Get Alert |
03/24/2023 | Buy Now | 1877.59% | Oppenheimer | Matthew Biegler | → $18 | Reiterates | → Outperform | Get Alert |
03/24/2023 | Buy Now | 1218.39% | JMP Securities | Silvan Tuerkcan | → $12 | Reiterates | → Market Outperform | Get Alert |
03/24/2023 | Buy Now | 2317.05% | Baird | Jack Allen | $38 → $22 | Maintains | Outperform | Get Alert |
03/24/2023 | Buy Now | 1822.65% | HC Wainwright & Co. | Swayampakula Ramakanth | $20 → $17.5 | Reiterates | → Buy | Get Alert |
02/13/2023 | Buy Now | 1218.39% | JMP Securities | Silvan Tuerkcan | → $12 | Reiterates | → Market Outperform | Get Alert |
01/19/2023 | Buy Now | 1218.39% | JMP Securities | Silvan Tuerkcan | $15 → $12 | Maintains | Market Outperform | Get Alert |
11/14/2022 | Buy Now | 1877.59% | Oppenheimer | Matthew Biegler | $27 → $18 | Maintains | Outperform | Get Alert |
11/11/2022 | Buy Now | 1547.99% | Barclays | Carter Gould | $26 → $15 | Maintains | Overweight | Get Alert |
08/15/2022 | Buy Now | 2097.32% | HC Wainwright & Co. | Swayampakula Ramakanth | $26 → $20 | Maintains | Buy | Get Alert |
07/26/2022 | Buy Now | 1877.59% | Wedbush | David Nierengarten | → $18 | Initiates | → Outperform | Get Alert |
05/24/2022 | Buy Now | 339.46% | Goldman Sachs | Andrea Tan | $6 → $4 | Maintains | Neutral | Get Alert |
05/13/2022 | Buy Now | 1547.99% | JMP Securities | Silvan Tuerkcan | $30 → $15 | Maintains | Market Outperform | Get Alert |
04/27/2022 | Buy Now | 559.2% | Goldman Sachs | Andrea Tan | → $6 | Initiates | → Neutral | Get Alert |
03/21/2022 | Buy Now | 2756.52% | Barclays | Carter Gould | $56 → $26 | Maintains | Overweight | Get Alert |
03/16/2022 | Buy Now | 3195.98% | JMP Securities | Silvan Tuerkcan | $40 → $30 | Maintains | Market Outperform | Get Alert |
12/17/2021 | Buy Now | 2756.52% | HC Wainwright & Co. | Swayampakula Ramakanth | — | Initiates | → Buy | Get Alert |
12/03/2021 | Buy Now | 4074.91% | Baird | Jack Allen | — | Initiates | → Outperform | Get Alert |
12/02/2021 | Buy Now | 3195.98% | Oppenheimer | Matthew Biegler | — | Initiates | → Outperform | Get Alert |
10/19/2021 | Buy Now | 4294.64% | JMP Securities | Silvan Tuerkcan | — | Initiates | → Market Outperform | Get Alert |
The latest price target for Vor Biopharma (NASDAQ:VOR) was reported by JMP Securities on May 13, 2024. The analyst firm set a price target for $12.00 expecting VOR to rise to within 12 months (a possible 1218.39% upside). 13 analyst firms have reported ratings in the last year.
The latest analyst rating for Vor Biopharma (NASDAQ:VOR) was provided by JMP Securities, and Vor Biopharma reiterated their market outperform rating.
There is no last upgrade for Vor Biopharma
There is no last downgrade for Vor Biopharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vor Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vor Biopharma was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
While ratings are subjective and will change, the latest Vor Biopharma (VOR) rating was a reiterated with a price target of $12.00 to $12.00. The current price Vor Biopharma (VOR) is trading at is $0.91, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.